Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVI-GUARD
- Development stage
- Discontinued
- Lead developer
- Sorrento Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
COVI-GUARD (STI-1499) is a fully human monoclonal antibody developed to neutralize SARS-CoV-2, the virus responsible for COVID-19. It was identified from Sorrento Therapeutics' proprietary G-MAB antibody library after screening billions of candidates. The antibody binds to and neutralizes SARS-CoV-2, including the D614G variant, by preventing viral entry into healthy cells. Preclinical studies demonstrated 100% inhibition of viral infection in vitro and potent activity in animal models (Syrian Golden Hamsters). The drug is being developed as a potential treatment for hospitalized COVID-19 patients and may allow for lower dosing compared to other antibodies due to its high potency[1][2][8].
- Brand names
- COVI-GUARD
- Other names
- STI-1499STI1499STI 1499
02
Targets
S1 (SARS-CoV-2 spike S1 subunit)
Beyond the preview
Go deeper on COVI-GUARD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVI-GUARD.